2605.HK

Bus information provider  MetaLight Inc. (2605.HK) suffered a bruising Hong Kong debut on Tuesday, as its shares opened down 22% at HK$7.60 on their first trading day. The stock continued to fall through the morning session, closing at HK$6.99 by the midday break, down 28% from its IPO price.

The company sold 24.9 million shares at HK$9.75 apiece, with 10% allocated to the public offering for local Hong Kong investors that was oversubscribed by 273 times. The international placement was oversubscribed by nearly 1.5 times.

Metalight’s flagship Chelaile app provides real-time public-transit information in China and has 298 million users. The listing raised net proceeds of nearly HK$160 million ($20.4 million). MetaLight said it will use over 75% of the proceeds to enhance its technical capabilities and for marketing efforts. Another 15% will go to team recruitment, with the rest reserved for general corporate purposes.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

WeRide is enjoying a payoff from expanding its global taxi flee

Robotaxi rollout drives faster earnings pace at WeRide

The driverless technology company is enjoying a payoff from expanding its global taxi fleet, with quarterly revenues surging and losses continuing to shrink Key Takeaways: Third-quarter revenue more than doubled,…
Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…